A Phase 2, Randomized, Double-Blind, Placebo-Controlled, Multi-Center Trial of the Effects of GC4419 on Severe Oral Mucositis in Patients Receiving Cisplatin + IMRT for Locally Advanced Non-Metastatic SCC of the Oral Cavity/Oropharynx
Active, no longer recruiting
Phase of Trial: Phase II
Latest Information Update: 14 Jul 2017
At a glance
- Drugs GC 4419 (Primary)
- Indications Mucositis
- Focus Therapeutic Use
- Sponsors Galera Therapeutics
- 15 Jun 2017 Top-line results from this trial are expected in 4Q 2017 according to a Galera Therapeutics media release.
- 15 Jun 2017 Status changed from recruiting to active, no longer recruiting according to a Galera Therapeutics media release.
- 03 Feb 2016 According to a Galera Therapeutics Inc. media release, GC4419 received Fast Track designation for the prevention of radiation-related oral mucositis in patients with head and neck cancer.